Gilead’s Magrolimab Mostly Back On Track As FDA Lifts AML, MDS Holds
Executive Summary
The clinical holds, initially announced in January, raised concerns about the company losing its edge in CD47-targeting drugs. Partial holds on the DLBCL and myeloma programs remain in place.
You may also be interested in...
Ichnos’ Early-Stage Myeloma Asset Designed To Avoid ‘Pitfalls’ Of Magrolimab
Glenmark’s innovation subsidiary, Ichnos, highlights encouraging early data for lead bispecific antibody assets and hopes to accelerate these via licensing and partnership deals.The US-based arm also points to the tough biopharma financing market where investors are no longer satisfied with just the “preclinical story”.
COVID-19 Gives US Biopharma Plenty Of Q1 Cover
Pfizer, Merck, Eli Lilly and Gilead all benefited from the sale of vaccines and treatments for COVID-19, but the long-term growth prospects remain uncertain, and more so for some than others.
Finance Watch: HilleVax, Belite Bio Launch First Two Biopharma IPOs In Q2
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.